Drug Trial Radar · NCT07169994
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
414
Planned (sponsor's estimate)
Start
Sep 2, 2025
Primary completion
Sep 1, 2026
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors
Conditions
- Advanced Solid Tumors
- Breast Cancer
- Non Small Cell Lung Cancer
Interventions
YL202 for injection; Toripalimab injectionDrug
Part 1: YL202 and Toripalimab will be administered intravenously. Part 3: participants will receive escalating doses of YL202 and fixed dose of Toripalimab until YL202 doses for optimization are determined. Dose expansion stage: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Toripalimab
YL202 for injection; Furmonertinib Mesilate TabletsDrug
Part 2: YL202 will be administered intravenously,Furmonertinib Mesilate Tablets will be administered orally. Dose escalation stage: participants will receive escalating doses of YL202 and fixed dose of Furmonertinib Mesilate until YL202 doses for optimization are determined. Part 4: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Furmonertinib Mesilate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Nature and frequency of dose-limiting toxicity (DLT)Time frame: 21 days after the first dose was administered to each subject.
- Nature and frequency of adverse events (AEs)Time frame: 42 days after the end of treatment (EOT).
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital(The First Affiliated Hospital of Ustc)
Hefei, Anhui, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Not yet recruiting
Meizhou People's Hospital(Huangtang Hospital)Meizhou Academy of Medical Sciences
Meizhou, Guangdong, China · Not yet recruiting
Ghang xi Medical University Cancer Hospital
Nanning, Guangxi, China · Not yet recruiting
Affiliated Hospital Of Hebei University
Baoding, Hebei, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Anyang Cancer Hospital
Anyang, Henan, China · Not yet recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Not yet recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Not yet recruiting
The First People's Hospital of Changde City
Changde, Hunan, China · Not yet recruiting
Jiangsu Province Hospital(The First Affiliated Hospital With Nanjing Medical University, Jiangsu Women And Children Health Hospital)
Nanjing, Jiangsu, China · Not yet recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Affiliated Zhongshan Hospital Dalian University
Dalian, Liaoning, China · Not yet recruiting
Liaoning cancer hospital &institute
Shenyang, Liaoning, China · Not yet recruiting
Affiliated Zhongshan Hospital Dalian University
Jinan, Shandong, China · Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Not yet recruiting
Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital
Sichuan, Sichuan, China · Not yet recruiting
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.